Agilent tech aids in FDA approval of Autolus CAR T therapy

SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE: A), a $34.4 billion market cap company with a strong financial health rating according to InvestingPro, has contributed to the FDA approval of Autolus Therapeutics’ new CAR T therapy, AUCATZYL®, by providing its xCELLigence Real-Time Cell Analysis (RTCA) technology. This advanced cell analysis tool played a crucial role in developing and validating the potency assay for AUCATZYL®.

The xCELLigence RTCA system is distinguished by its ability to monitor cellular behaviors continuously and in real-time, without the need for labels or dyes. It measures electrical impedance to give researchers detailed information on cell count, viability, and morphology. This method contrasts with traditional endpoint assays by offering ongoing insights that can lead to more precise and timely decisions in drug development.

Dr. Xiaobo Wang, Vice President and General Manager of the Cell Function and Phenotyping Business at Agilent, expressed pride in Agilent’s involvement in this advancement for cancer treatment. David Brochu, Chief Technical Officer at Autolus Therapeutics, acknowledged the importance of Agilent’s support and technology in meeting the rigorous standards for FDA approval.

Agilent and Autolus Therapeutics will jointly present at the 2025 Hybrid US Bioassay Conference in Tucson, Arizona, today. Their Main Session Podium Talk will cover the lessons learned in measuring the potency of CAR T cell products and the significance of partnerships in this field.

Agilent, a global leader in analytical and clinical laboratory technologies, supports scientific innovation and the development of therapies that improve health outcomes. The company, which generated $6.53 billion in revenue with a healthy 54% gross profit margin, maintains a strong dividend history of 14 consecutive years. Currently trading near its 52-week low, InvestingPro analysis indicates the stock is slightly undervalued, with 12 additional exclusive insights available to subscribers. The company, which employs approximately 18,000 people worldwide, continues to offer a range of solutions encompassing instruments, software, and services that deliver trusted answers to complex questions.

This news is based on a press release statement from Agilent Technologies Inc. For comprehensive analysis and detailed financial metrics, including the company’s Fair Value estimate and growth prospects, investors can access the full Pro Research Report, available exclusively on InvestingPro.

In other recent news, Agilent Technologies reported strong earnings for the first quarter of 2025, surpassing Wall Street expectations with an earnings per share of $1.31 against a forecast of $1.27. The company’s revenue reached $1.68 billion, slightly above the anticipated $1.67 billion, driven by growth in PFAS testing and food markets. Stifel analysts maintained a Buy rating for Agilent, noting the company’s consistent performance and setting a price target of $151. Despite a softer outlook for the second quarter, Agilent’s full-year guidance remains unchanged, anticipating around 3% organic growth.

Additionally, Agilent’s PD-L1 IHC 28-8 pharmDx kit received two new companion diagnostic indications approvals in the European Union, expanding its use for early-stage non-small cell lung cancer and previously untreated advanced melanoma. This development highlights Agilent’s commitment to companion diagnostics, reinforcing its position in the life sciences sector. The company also reported ongoing strategic initiatives aimed at margin expansion, as well as improvements in pharmaceutical activity and contributions from PFAS testing. Overall, Agilent’s recent performance and strategic moves reflect its resilience and adaptability in a challenging market environment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.